All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak to Courtney DiNardo, MD Anderson Cancer Center, Houston, US. We asked, What do long-term data from the VIALE-A trial tell us about treatment with azacitidine plus venetoclax?
What do long-term data from the VIALE-A trial tell us about treatment with azacitidine plus venetoclax?
DiNardo discusses findings from the long-term follow-up of the VIALE-A trial presented at ASH, including the continued improved overall survival of patients treated with azacitidine plus venetoclax compared with azacitidine alone. Covering topics such as prognostic mutational features and European LeukemiaNet risk groups, DiNardo comments on how use of this combination therapy impacts patients with acute myeloid leukemia in the long term.
Visual Abstract | Venetoclax plus azacitidine for patients with IDH1/2 mutated AML who are ineligible for intensive chemotherapy
The AML Hub is delighted to present a visual abstract representing key data pooled from the phase III VIALE-A trial...
Editorial theme | Novel combination therapies using targeted agents
This article provides a summary of content relating to novel agent-containing combinations to date & introduces the new editorial theme of ‘Novel combination therapies using...
Subscribe to get the best content related to AML delivered to your inbox